Sector News

Next stop in AstraZeneca fire sale: China

October 14, 2016
Life sciences

AstraZeneca keeps hanging out the “for sale” sign. While diabetes care is an expanding market in many emerging markets like China, this latest deal reflects the British pharma’s strategy of shifting toward core therapeutic areas, such as oncology and respiratory, and selling off non-core assets.

Chinese revenues for Byetta and Bydureon are growing but remained marginal over the past two years. Total sales attributable to the two drugs in China hit $11.3 million in 2014 and $14.6 million in 2015, 3SBio said.

Under the deal, AstraZeneca grants an exclusive license to Hongkong Sansheng, a wholly-owned subsidiary of 3SBio, for the commercialization of the licensed products in China. AstraZeneca still retains rights to license the products outside China along with certain rights not tied to commercialization of the licensed products in China.

Byetta was approved by Chinese regulators in August 2009, and AstraZeneca submitted an application for approval this past May for Bydureon.

AstraZeneca is under pressure to meet CEO Pascal Soriot’s ambitious target of $45 billion in annual revenues by 2023. That goal is looking increasingly unattainable, especially as revenue from drugs like Crestor drops in the face of generic competition.

Yet AstraZeneca has high hopes for its efforts in oncology, and has seen promising early commercial returns from lung cancer drug Targrisso. But the real jewel is the experimental checkpoint inhibitor durvalumab, which is being tested in a range of cancers. Stiff competition could hurt AstraZeneca’s chances of growing revenue in this space, however.

By Joe Cantlupe

Source: BioPharma Dive

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach